'All In': a pragmatic framework for COVID-19 testing and action on a global scale.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
08 06 2020
Historique:
pubmed: 7 5 2020
medline: 18 6 2020
entrez: 7 5 2020
Statut: ppublish

Résumé

Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance toward realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts toward enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework has the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks.

Identifiants

pubmed: 32375201
doi: 10.15252/emmm.202012634
pmc: PMC7267598
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12634

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM125498
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM118228
Pays : United States

Informations de copyright

© 2020 The Authors. Published under the terms of the CC BY 4.0 license.

Références

Bull World Health Organ. 2017 Sep 1;95(9):639-645
pubmed: 28867844
J Immunotoxicol. 2020 Dec;17(1):51-58
pubmed: 32124652
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32317257

Auteurs

Syril D Pettit (SD)

Health and Environmental Sciences Institute, Washington, DC, USA.

Keith R Jerome (KR)

Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

David Rouquié (D)

SAS Bayer Crop Science, Sophia Antipolis, France.

Bernard Mari (B)

Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.

Pascal Barbry (P)

Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.

Yasunari Kanda (Y)

National Institute of Health Sciences, Kanagawa, Japan.

Mineo Matsumoto (M)

Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

Susan Hester (S)

Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.

Leah Wehmas (L)

Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.

Jason W Botten (JW)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Emily A Bruce (EA)

Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH